CytRx CEO Steven Kriegsman is scheduled to present at the Roth Capital Partners’ annual growth stock conference on Feb. 19, 2004, the company said this week.
Kriegsman is expected to highlight CytRx’s recent collaborations in the field of RNAi and small-molecule drug development, and also give an overview of the company’s other drug development programs.
The Roth meeting is scheduled for Feb. 16-19 at the St. Regis Monarch Beach Resort and Spa in Dana Point, Calif.
CytRx also announced this week that Bruce Spiegelman has joined the scientific advisory board of the company’s subsidiary Araios.
Spiegelman, said CytRx, is a professor of cell biology at Harvard Medical School’s Dana Farber Cancer Institute. His work focuses on the molecular basis of cell differentiation and tissue development, using adipogenesis as a model system.
Spiegelman holds a BS from the College of William and Mary and a PhD from Princeton University.
Also on Araios’ scientific advis- ory board are Michael Czech, professor and chair of molecular medicine at the University of Massachusetts Medical School, Ronald Kahn, president and director of the Joslin Diabetes Center, and Luciano Rossetti, professor and director of diabetes research at the Albert Einstein College of Medicine.